AIM ImmunoTech Receives NYSE American Notice of Delisting and Appeals Decision
AIM Immunotech Announces NYSE American Notice of Delisting and Appeal
April 25, 2023
LAKEWOOD, Colo., April 25, 2023 /PRNewswire/ -- AIM Immunotech, Inc. (NYSE American: AIMI), a biotechnology company focused on the development and commercialization of innovative diagnostic and therapeutic products, today announced that it has received a notice of delisting from the NYSE American LLC ("NYSE American") due to the Company's failure to maintain the minimum listing standards.
The notice of delisting states that the Company's stock price has fallen below the minimum listing standard of $1.00 per share for a period of 30 consecutive trading days, as required by the NYSE American's continued listing standards. As a result, the Company's common stock will be delisted from the NYSE American effective May 25, 2023, unless the Company appeals the decision and is able to demonstrate compliance with the continued listing standards.
AIM Immunotech has decided to appeal the notice of delisting and is working to demonstrate compliance with the continued listing standards. The Company is also exploring alternative listing options and will provide updates as necessary.
"We are disappointed by the notice of delisting, but we are committed to regaining compliance with the NYSE American's continued listing standards," said John T. Coffey, CEO of AIM Immunotech. "We are exploring all available options to maintain our listing and continue to provide value to our shareholders."
The Company's common stock will continue to trade on the NYSE American until the effective date of the delisting, which is May 25, 2023. AIM Immunotech will provide further updates as necessary.
About AIM Immunotech, Inc.
AIM Immunotech, Inc. is a biotechnology company focused on the development and commercialization of innovative diagnostic and therapeutic products. The Company's mission is to improve patient outcomes by providing accurate and timely diagnostic information, and by developing novel therapeutic approaches that address unmet medical needs. AIM Immunotech is headquartered in Lakewood, Colorado. For more information, visit our website at www.aimimmunotech.com.